Since reaching historically low rates, many sexually transmitted infections have re-emerged in the United States. Of particular concern is the continued emergence of antibiotic resistance in Neisseria gonorrhoeae.
Since achieving historic lows, the rates of many sexually transmitted infections has been increasing in the United States. The problem is highlighted by the continued emergence of antibiotic resistance in Neisseria gonorrhoeae.
According to a new report, serious gaps exist in the research pipeline regarding the development of prevention and treatment options for sexually transmitted infections such as gonorrhea, chlamydia, and syphilis.
Just-released research findings indicate that a potential rapid chlamydia test delivers accurate results in about 30 minutes, which could make it possible for patients to be treated right away. Such point-of-care testing could help eliminate the need for follow-up appointments because patients would receive treatment at the time of diagnosis, say researchers.
Since 2006, the Centers of Disease Control and Prevention has recommended the use of expedited partner therapy (EPT) for treatment of sexually transmitted infections such as gonorrhea and chlamydia, but the infection rate continues to climb.
2.3 million cases of chlamydia, gonorrhea, and syphilis were reported in 2017
October 25, 2018
Nearly 2.3 million cases of chlamydia, gonorrhea, and syphilis were diagnosed in the United States in 2017, preliminary data indicate. This number surpasses the previous high level in 2016 and marks the fourth consecutive year of sharp increases in sexually transmitted infections.
This article reviews the current status of expedited partner therapy (EPT), which involves treating the heterosexual partners of patients diagnosed with chlamydia or gonorrhea by providing the medication or a prescription for the patient to give to the partner without a healthcare provider first examining the partner.